CytomX Therapeutics Stock Forecast

CTMX's stock price has decreased by -53.38% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.52, with a low estimate of 2.50 and a high estimate of 8.00. The average target predicts an increase of 617.91% from the current stock price of 0.77.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.50	$5.52	$8.00	$8.00
Change	+225.14%	+617.91%	+940.45%	+940.45%

Analyst Ratings

The average analyst rating for CytomX Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	1	1	1	1	1	1
Buy	2	2	2	2	2	2
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Catanzaro Piper Sandler	Piper Sandler	Buy Maintains $3.25 → $2.5	Buy	Maintains	$3.25 → $2.5	+225.14%	Apr 14, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Mar 7, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Jan 7, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Nov 11, 2024
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Sep 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

96.24M

from 138.10M

-30.31%

from 138.10M

Revenue Next Year

38.76M

from 96.24M

-59.73%

from 96.24M

EPS This Year

0.01

from 0.38

-97.64%

from 0.38

EPS Next Year

-0.61

from 0.01

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	68.43M	37.31M	53.16M	101.21M	138.10M	96.24M	38.76M	18.19M
Revenue Growth	154.36%	-45.47%	42.48%	90.38%	36.45%	-30.31%	-59.73%	-53.07%
EPS	-1.40	-1.81	-1.51	-0.01	0.38	0.01	-0.61	-0.65
EPS Growth	-	-	-	-	-	-97.64%	-	-
Forward PE	-	-	-	-	-	86.15	-	-
No. Analysts	-	-	-	-	-	8	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	163.3M	107.1M	52.5M
Avg	96.2M	38.8M	18.2M
Low	49.0M	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	18.2%	11.3%	35.4%
Avg	-30.3%	-59.7%	-53.1%
Low	-64.5%	-	-

EPS Forecast

EPS	2025	2026	2027
High	0.29	0.15	-0.53
Avg	0.01	-0.61	-0.65
Low	-0.43	-0.99	-0.83

EPS Growth

EPS Growth	2025	2026	2027
High	-23.5%	1,547.1%	-
Avg	-97.6%	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.